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Abstract: Recent studies have highlighted the potential protective role of omega-3 polyunsaturated fatty
acids (n-3 PUFA) in asthma. This study aimed at determining the association between seafood intake,
serum PUFA composition and clinical endpoints of asthma in adults. A cross-sectional study of
642 subjects used the European Committee Respiratory Health Survey (ECRHS) questionnaire,
skin prick tests, spirometry and methacholine challenge tests following ATS guidelines. Sera was
analysed for n-3 and n-6 PUFA composition. Subjects had a mean age of 34 years, were largely female
(65%) and 51% were current smokers. While 99% reported fish consumption, rock lobster, mussels,
squid and abalone were also consumed less frequently. The prevalence of asthma symptoms was 11%,
current asthma (ECRHS definition) was 8% and non-specific bronchial hyperresponsiveness (NSBH)
was much higher (26%) In adjusted models the n-3 PUFAs 20:5 (EPA) and 22:5 (DPA) were significantly
associated with a decreased risk of having NSBH. Total n-3 PUFA composition was associated with
decreased NSBH risk (OR = 0.92), while high n-6 PUFA composition was associated with an increased
risk (OR = 1.14).
Keywords: non-specific bronchial hyperresponsiveness; polyunsaturated fatty acids; omega-3
fatty acids; omega-6 fatty acids; asthma clinical endpoints
1. Introduction
Asthma afflicts up to 334 million people worldwide and its incidence has been increasing for
the past three decades with 250,000 deaths attributed to asthma annually [1,2]. Asthma incidence
has nearly doubled in the past thirty years and despite an increase in treatment options up to 50%
of asthma patients do not derive benefit from drug treatment available to them. There is therefore
a growing interest in non-pharmacologic treatment options that may potentially reverse this trend.
Dietary change is one of several environmental factors implicated in the rising asthma incidence and
therefore represents a potentially modifiable factor to stem the tide of the asthma epidemic.
In the past two decades increasing interest has been shown in the role of dietary polyunsaturated
fatty acids (PUFAs) [3–5]. The hypothesis underlying this assumption is linked to the dramatic
change in patterns of PUFA consumption in the typical Western diet with an increasing trend for the
consumption of omega-6 (n-6) PUFA mainly found in vegetable oils and a decline in consumption
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of omega-3 (n-3) PUFA which is mainly found in marine oils [6–8]. It is primarily a lower n-3PUFA
dietary intake which is contributing to the increasing morbidity of asthma and allergic disease [9].
Biomarkers that better reflect this deficiency such as the red blood cell (RBC) eicosapentaenoic acid
(EPA) + docosapentaenoic acid (DPA) expressed as a percentage weight of total RBC membrane
fatty acids or the “omega index” have been proposed in view of the relative imprecision and lack of
specificity of the ratio between n-3 and n-6 fatty acids [10].
The role of PUFA as immune modulators has been extensively studied in relation to lung
health [11–13]. The most abundant n-6 PUFA in the Western diet, linoleic acid (LA), is converted to
arachidonic acid (AA), a precursor of both prostaglandin E2 and leukotriene B4, produced by mast
cells and eosinophils. Both prostaglandin and leukotriene are potent bronchoconstrictors and exhibit
pro-inflammatory properties in allergic disease. In contrast alpha linolenic acid (ALA), an n-3 PUFA,
is converted to EPA, which inhibits arachidonic acid and thereby suppresses production of the
n-6 PUFA-derived eicosanoid inflammatory mediators. EPA functions as a precursor for bioactive
molecules such as resolvins, protectins and maresins. These pro-resolving mediators have important
anti-inflammatory properties [11]. Recent studies have shown that the imbalance between these
pro- and anti-inflammatory molecules results in the exacerbation of inflammation as observed in the
airways of asthmatics.
Research has also focused on fish intake and n-3 supplementation in relation to risk of asthma.
Various studies of pregnant women have evaluated the relationship between n-3 PUFA supplementation,
fish oil intake or dietary consumption and respiratory health outcomes in offspring linked to asthma.
A randomized control trial demonstrated that maternal supplementation with fish oil, containing n-3
long-chain (LC)PUFA, may have prophylactic potential in the long-term prevention of asthma in
offspring [13]. In a double blind RCT, Bisgaard et al. showed a reduction in the risk of persistent
wheeze or asthma in offspring by approximately 7%, or one third in those offspring whose mothers
received supplementation with n-3 LC-PUFA in the third trimester of pregnancy [14].
Whilst some studies have suggested that maternal fish intake during pregnancy is associated with
a lowered risk of asthma among offspring in infancy and childhood, the current evidence indicates
that atopic outcomes such as allergic rhinitis, wheeze and eczema are unaffected by maternal fish
intake [11,15]. Fish intake in infancy has however been shown to reduce the risk of allergic rhinitis and
eczema in children but not that of wheeze and asthma. The authors concluded that it is the intake of
fish and not n-3-LC-PUFA which potentially has a protective effect on the risk of allergic disease in
childhood and that randomized controlled trials should be conducted to confirm this [15].
Observational studies among adults, in general, have however produced inconsistent results.
Several studies have shown n-3 PUFA intake to be associated with lower asthma symptom prevalence,
asthma incidence or fractional exhaled nitric oxide (FeNO) levels and improved lung function [16–19].
Other studies have demonstrated that a diet high in marine n-3 PUFA (fish oil) may have beneficial
effects by reducing airway hyperresponsiveness and that fish oil supplementation may reduce the
severity of exercise-induced bronchoconstriction in adults [20,21].
In examining the relationship between fatty acids and respiratory health outcomes, studies have
also investigated the frequency of dietary intake of fish or seafood as a proxy measure for n-3 PUFA
consumption. A strong correlation between habitual fish intake and serum EPA and docosa-pentaenoic
acid (DPA) levels has been demonstrated, suggesting that serum concentration of n-3 PUFA is a useful
biomarker for dietary fish intake [22,23]. Plasma n-3 PUFA are also significantly higher in women than in
men and 20% higher in fish-oil consumers compared to non-fish-oil consumers [23]. While most studies
have relied on self-reporting of dietary intake to estimate n-3 PUFA intake, studies evaluating serum
fatty acid composition and asthma outcomes in young adults have demonstrated consistent associations
between the composition of specific n-6 fatty acids and higher asthma risk using various definitions of
asthma outcomes [24]. A significant protective effect for asthma incidence related to n-3 PUFA intake
has also been shown in a recent large cohort study of young adults [25].
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The aim of this study was to evaluate the relationship between serum fatty acid status and various
asthma endpoints in a predominantly female working population employed in fish processing factory
and living in a coastal village. Various clinical endpoints of asthma were evaluated to assess the
strength and consistency of associations observed.
2. Materials and Methods
2.1. Study Design, Population and Sampling
This secondary study data is nested in a cross-sectional study, which was originally designed to
specifically determine the prevalence and risk factors for occupational asthma due to fish allergens in
seafood processing workers. Detailed explanation of the methodology has been published elsewhere [26].
A cross-sectional study of 642 of currently employed workers was conducted in two fish processing
plants working along the West Coast of South Africa. All 260 workers in Factory A were investigated.
For efficiency reasons, 382 workers from Factory B were included from a total workforce of 1275 workers.
These workers were chosen using stratified random sampling based on the department in which
they worked. Ethical clearance of the protocol was obtained from the University of Cape Town (Ethics
No. 109/99, 30/4/99), University of Michigan and the National Institute of Health (USA) prior to the
study being conducted. Each participant signed informed consent prior to being tested.
2.2. Health Outcome Measurements
2.2.1. Questionnaire
Each worker answered a standard questionnaire of the European Community Respiratory Health
Survey [27]. The questionnaire was modified to include questions relating to current and previous
employment, exposure to seafood aerosols (ascertained on subjective assessment of visibility of others
in the work environment), tobacco smoke and patterns of seafood consumption. The questionnaire
was also adapted for local conditions and translated into local languages, and back translated to assess
validity and reproducibility. It was administered by trained interviewers in whichever language the
worker was most fluent.
2.2.2. Skin Prick Tests
Skin prick tests (SPT) were performed on each worker using standard common local
aeroallergens (ALK-Abelló, A/S, Hørsholm, Denmark) that included house dust mite (Dermatophagoides
pteronyssinus), bermuda grass (Cynodon dactylon), rye grass (Lolium perenne), cockroach (Blatella germanica),
cat (Felis domesticus), dog (Canis familiaris), mouldmix (Cladosporium herbarum), Alternaria (Alternata
Fusarium), Aspergillus (Aspergillus fumigatus) and mussel (Mytilus edulis) (LETI Alergia, Barcelona, Spain).
The specific seafood extracts were prepared in-house. Histamine dihydrochloride was used as positive
control and diluent of glycerol/sodium chloride as a negative control. Workers were instructed not to
take any anti-histamines for three days prior to the test. Skin prick tests for atopy were administered on
625 subjects. A positive SPT was regarded as a wheal read 15 min after testing having a diameter (mean
of two perpendicular measures) of 3 mm more than the negative control. Areas of wheal were traced on
clear tape and stored for later verification. Atopic status was considered to be present if the SPT to one
or more common aeroallergens was positive [28].
2.2.3. Analysis of Serum Total Phospholipid Fatty Acid Composition
For analysis of serum total phospholipid fatty acid composition, serum was thawed and extracted
with chloroform/methanol (2:1; v/v) according to a modified method of Folch et al. containing 0.01%
butylated hydroxytoluene (BHT) as an antioxidant. [19] The total phospholipid band was scraped off
and analysed for fatty acid composition as described previously [29]. The fatty acid methyl-esters
(FAME) were identified by comparison of the retention times to those of a standard FAME mixture
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(Nu-Chek-Prep Inc., Elysian, MT, USA). The concentrations of individual fatty acids were measured,
and the results expressed as weight percentage (% wt/wt) of the total phospholipid fatty acids
(composition). The relative composition of one of the major marine n-3 PUFA, EPA (20:5n-3) was used
as an index of habitual seafood consumption.
2.2.4. Spirometry
American Thoracic Society (ATS) guidelines were followed for the spirometry tests [30]. Vitallograph
S model bellows volume-time spirometers, calibrated at least twice a day with a three-liter syringe,
were used [31]. Lung volumes obtained by spirometry were adjusted for body temperature and
atmospheric pressure. Special instructions were given to workers not to smoke tobacco (at least one hour
before) and to stop anti-asthmatic inhalers (4 h before) or oral asthma medications (8 h before) prior to
the test. Pulmonary function reference values of the European Community for Coal and Steel (ECCS)
with lower limits corresponding to the 95th percentile were used where appropriate [32]. Spirometry
results with acceptable traces were obtained for 582 subjects.
2.2.5. Methacholine Challenge Testing
Non-specific inhalation challenge testing using methacholine chloride powder mixed with normal
saline was performed during the working day and scheduled throughout the working week using
an abbreviated protocol. The two-minute tidal breathing method was used [33]. The diluent was
administered using the Salter 8900 Series nebulizer set (reference 8900, Salter Labs, Arvin, CA, USA),
with a nebulizer output volume 0.13 mL per minute ± 10% and particle size < 5 microns (85%).
In all subjects eligible for methacholine challenge test (MCT), saline diluent was first administered
before inhalations of methacholine were done every five minutes. Subjects underwent either a short,
medium or full protocol depending on the presence of asthma symptoms and baseline lung function.
If the Forced Expiratory Volume in 1 s (FEV1) was 70–80% of predicted or symptoms were present,
concentrations commenced at 0.03 mg/mL and doubled until 16 mg/mL (long protocol). In subjects
with an asthma history or symptoms controlled and FEV1 80% of predicted, concentrations commenced
at 0.125 mg/mL and doubled until 16 mg/mL (medium protocol). Those with no symptoms or
history of asthma and FEV1 was 80% of predicted, concentrations of 2, 4, 8 and 16 mg/mL
were used (short protocol). This short protocol procedure was completed in 35 min. A positive
methacholine challenge test with a PC20 8 mg/mL was considered highly suggestive of asthma [34].
Subjects in whom MCT was contraindicated, such as those with acute asthma symptoms or a
baseline FEV1 < 1.5 L or FEV1 < 70% predicted, a bronchodilator (400 µg salbutamol) was administered
instead [35]. A change in FEV1 of 12% and 180 mL increase after 10 min of bronchodilator administration
was considered to confirm the presence of NSBH. The methacholine challenge tests were conducted on
542 subjects.
2.3. Definitions
Key associations of interest involved investigating the relationships between seafood intake,
serum polyunsaturated fatty acids and clinical endpoints for asthma. Definitions of the key clinical
outcome variables are presented below and include the previously validated operational definition
of current asthma as used in the European Community Respiratory Health study (ECHRS), which is
widely used in asthma prevalence surveys [27].
2.3.1. Predictor Variables
Data on frequency of fish and seafood intake were collected in a standardized format and coded
in a uniform manner. Serum polyunsaturated fatty acid levels were reported as per laboratory analysis
and expressed as the weight % of total phospholipid composition.
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2.3.2. Asthma-Related Endpoints of Interest
Atopy: A positive SPT with a wheal read 15 min after testing that had a diameter (mean of two
perpendicular measures) of ≥3 mm more than the negative control to any allergen extract.
Asthma symptoms: Affirmative response to any of: “Have you had an attack of asthma in the
last 12 months?”, “Have you been woken by an attack of shortness of breath in the last 12 months?”,
“Have you been woken up with a feeling of tightness in your chest any time in the last 12 months?”
Current as asthma (ECRHS): Presence of either an attack of shortness of breath, an attack of
asthma or use of asthma medication.
Non-specific bronchial hyperresponsiveness: A positive methacholine challenge test with a PC20
≤ 8 mg/mL causing a drop in FEV1 of 20% or more or an increase in FEV1 of ≥12% after 10 min of
bronchodilator administration on baseline spirometry.
2.3.3. Covariates
Standard questionnaires were used to maintain consistency in the assessment of demographic
information, including data on age, and sex. Smoking status was classified into three groups: current,
former, or never.
2.4. Data Analysis
Statistical analyses were performed using STATA version 8 computer software (Stata Corp, College
Station, TX, USA) [36]. The general approach involved univariate, bivariate and multivariate analyses of
the outcomes of interest in relation to the predictors of interest. Generalized linear models were used for
logistic regression analyses with individual dichotomous outcomes. Key associations of interest involved
investigating the relationships between host factor attributes (age, gender, smoking, seafood intake and
serum fatty acid levels), in relation to atopy, non-specific bronchial hyperresponsiveness and asthma
clinical outcomes using bivariate unadjusted models. Separate multivariate logistic regression models
adjusting for age, gender and smoking were used to examine the role of specific serum PUFAs in relation
to asthma clinical endpoints. The serum concentrations of PUFA were treated as a continuous variable
and were analysed using logistic regression since the asthma outcomes used were binary. The resulting
risk estimates (odds ratio) are based on a one unit change in measured serum fatty acid.
3. Results
The study population comprised 642 workers from two seafood processing factories located in a
small fishing village on the West Coast of South Africa. The study subjects had a mean age of 35 years.
A large proportion of the workers investigated were female (64%) and lived in the village with a low
socio-economic background (see Table 1).
A high prevalence of smoking was found with 327 (51%) workers being current smokers at the
time of the survey. The population also reported a high prevalence of previous respiratory disease
with 13% reported being treated for tuberculosis in the past. Although a considerable proportion
(23%) reported ocular nasal symptoms, very few (2%) were receiving medical treatment for allergic
disease such as asthma or allergic rhinitis at the time of the survey. There were 7% of participants who
reported having doctor diagnosed asthma.
There were some significant differences found between males and females following
stratified analysis. Females reported higher rates of treatment for bronchitis (chi 5.94; p = 0.015) and
NSBH (chi 19.55; p ≤ 0.001) and lower rates of smoking (chi 16.70; p < 0.001) and childhood hayfever
(chi 23.27; p < 0.001).
A substantial proportion of the population were atopic (37%), with sensitization to indoor
aeroallergens such as house dust mite (25%) and cockroach (15%) being the most prevalent. One third
of the study population was sensitized to three or less allergens and a similar number displayed
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sensitization to at least one of the indoor aeroallergens (HDM, cockroach, cat, dog). Sensitization to
the mould group of allergens was relatively low (5%) (Table 2).
Table 1. Subject characteristics and asthma endpoints among fishing village inhabitants along the West
Coast of South Africa.
Subject Characteristics
Prevalence (%)
Mean/SD
(n = 642)
Age (yrs)
- Overall 34 (11)
- Female 34 (10)
- Male 35 (12)
Gender
- Female 414 (64%)
- Male 228 (36%)
Atopic status (%) (n = 625) 234 (37%)
Mean (SD) % predicted FEV1 (n = 582) 87 (14)
Smoking no (%)
- Current 328 (51%)
- Ex-smoker 72 (11%)
- Non-smoker 242 (38%)
Past medical history
Previous treatment for tuberculosis 81 (13%)
Previous treatment for chronic bronchitis 61 (9%)
Previous treatment for recurrent chest infections 36 (6%)
Doctor-diagnosed asthma 47 (7%)
History of allergic disease
No. with ocular-nasal symptoms 149 (23%)
No. with hayfever in childhood 30 (5%)
No. on current asthma treatment 29 (5%)
No. on current hayfever treatment 16 (2%)
Asthma endpoints
- Asthma symptoms 72 (11%)
- Current asthma 54 (8%)
- NSBH (n = 542) 141 (26%)
Table 2. Allergic sensitization profiles of seafood processing workers along the West Coast of the
Western Cape.
Sensitization Variables Prevalence (%)(n = 626)
All aeroallergens
Atopy (Positive to at least one aeroallergen) 234 (37%)
Positive to one aeroallergen
House dust mite 155 (25%)
Cockroach 94 (15%)
Rye grass 89 (14%)
Bermuda grass 57 (9%)
Dog 34 (5%)
Mouldmix 22 (4%)
Cat 20 (3%)
Aspergillus 14 (2%)
No. with one to three aeroallergens positive 211 (32%)
No. with greater than three aeroallergens positive 35 (6%)
At least one indoor allergen (HDM, cockroach, cat, dog) positive 200 (32%)
At least one pollen allergen (bermuda grass, rye grass) 98 (16%)
At least one mould allergen (mould mix, Aspergillus) 33 (5%)
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3.1. Serum Fatty Acid Profile
Laboratory analysis for serum fatty acid levels specifically for n-3 and n-6 PUFAs were obtained
for 633 subjects (Table 3). Linoleic acid (LA), arachidonic acid (AA) and dihomo-gamma-linolenic acid
(DGLA) had the highest mean serum levels among the n-6 PUFAs. Docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) had the highest mean serum levels among the n-3 PUFAs.
Table 3. Serum total phospholipid fatty acid profile (% weight) among fishing village inhabitants along
the West Coast of South Africa.
Type of Fatty Acid Mean PUFA Serum Level *Mean (SD)
n-3 series PUFAs (%)
18:3 ALA 0.07 (0.05)
20:5 EPA 2.10 (1.40)
22.5 DPA 1.11 (0.37)
22.6 DHA 5.65 (1.61)
n-6 series PUFAs (%)
18:2 LA 18.45 (3.78)
18:3 GLA 0.06 (0.07)
20:2 0.39 (0.17)
20:3 DGLA 2.26 (0.74)
20:4 AA 7.89 (1.94)
22:2 0.63 (0.21)
22:4 025 (0.13)
Mono-unsaturated fatty acids (MUFA)
18:1 n-9 (OA) 8.82 (1.66)
Total
n-3 8.93 (2.86)
n-6 29.93 (4.92)
Data are mean (SD) weight % ALA, alpha-linolenic acid; EPA, eicosapentaeoic acid; DPA, docosapentaenoic acid;
DHA, docosahexaenoic acid; LA, linolenic acid; GLA, γ-linolenic acid; DHGLA, dihomo-γ-linolenic acid; AA,
arachidonic acid; OA, oleic acid.
3.2. Asthma Outcomes
While the prevalence of NSBH was 26%, the prevalence of asthma symptoms was much lower
(11%) as was current asthma (based on the ECRHS definition), which was 8%. When evaluating
asthma outcomes, older age was associated with an increased odds of having asthma symptoms or
current asthma.
Females had a strongly increased odds of having NSBH (OR = 2.71). There was no relationship
between current smoking and any of the asthma outcomes (Table 4). In the unadjusted logistic
regression models, among the n-6 PUFAs, 18:2 (LA) [OR, 1.14; 95% CI, 1.08–1.21], 20:3 (DGLA)
[OR, 1.67; 95% CI, 1.27–2.20] and 20:4 (AA) [OR, 1.18; 95% CI, 1.06–1.31] were positively associated
with NSBH (Table 5). The n-6 PUFA 22:2 demonstrated a protective association with respect to
the presence of NSBH [OR, 0.29; 95% CI, 0.10–0.87]. However, none of the fatty acids showed any
association with atopy. Among the n-3 PUFAs 20:5 (EPA) and 22:5 (DPA) were associated with a
decreased risk of having NSBH.
In multivariate logistic regression models adjusting for age, gender and smoking, all the
demonstrated associations persisted, confirming that total n-3 fatty acids were associated with a
decreased risk while n-6 fatty acids an increased risk of having NSBH (Table 6). However, there were
no significant associations between any of the individual n-3 or n-6 PUFAs and asthma risk based
on asthma symptoms, although they were all generally in the expected direction of increased risk
(n-6 PUFA) or decreased risk (n-3 PUFA).
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Table 4. Prevalence of asthma endpoints and unadjusted logistic regression models in relation to
demographic characteristics among fishing village inhabitants along the West Coast of South Africa.
Prevalence (%)
Asthma Endpoints
Asthma
Symptoms
Current Asthma
(ECRHS) NSBH
a Atopy
72/642 (11%) 54/642 (8%) 141/ 542 (26%) 234/626 (37%)
Age (yrs) 1.03 (1.00–1.05) * 1.06 (1.03–1.08) *** 1.01 (0.99–1.03) 1.00 (0.99–1.02)
Female gender 0.85 (0.52–1.41) 0.86 (0.48–1.52) 2.71 (1.73–4.25) *** 0.95 (0.68–1.32)
Smoking
- Non-smoker 1.00 1.00 1.00 1.00
- Ex-smoker 1.59 (0.76–3.33) 2.83 (1.34–5.99) ** 1.63 (0.86–3.09) 0.96 (0.55–1.67)
- Current 0.89 (0.52–1.52) 0.80 (0.42–1.52) 1.32 (0.86–2.02) 1.06 (0.75–1.51)
* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Note: Each OR represents a separate regression model. Associations between
serum fatty acid profiles and asthma and atopy. a NSBH: non-specific bronchial hyperresponsiveness as reflected in
a positive methacholine challenge test.
Table 5. Unadjusted logistic regression models for asthma endpoints in relation serum phospholipid
(% weight) among fishing village inhabitants along the West Coast of South Africa.
Type of Fatty Acid Asthma Endpoints
Asthma Symptoms
n = 72
NSBH
n = 141
ATOPY a
n = 234
n-3 series
polyunsaturated
18:3 ALA - 0.18 (0.00–15.20) 0.63 (0.17–23.17)
20:5 EPA 0.95 (0.79–1.14) 0.68 (0.56–0.82) *** 0.98 (0.87–1.11)
22:5 DPA 0.87 (0.44–1.73) 0.38 (0.21–0.69) ** 1.15 (0.74–1.80)
22:6 DHA 1.06 (0.91–1.23) 1.01 (0.89–1.14) 1.01 (0.91–1.12)
n-6 series
polyunsaturated
18:2 LA 0.99 (0.93–1.06) 1.14 (1.08–1.21) *** 1.04 (0.99–1.08)
18:3 GLA 0.12 (0.00–19.41) 1.03 (0.04–25.99) 2.10 (0.19–23.81)
20:2 0.72 (0.13–4.03) 1.38 (0.50–3.82) 1.13 (0.44–2.93)
20:3 DGLA 1.13 (0.82–1.56) 1.67 (1.27–2.20) *** 1.06 (0.86–1.32)
20:4 AA 1.11 (0.98–1.27) 1.18 (1.06–1.31) ** 1.04 (0.95–1.13)
22.2 1.28 (0.42–3.84) 0.29 (0.10–0.87) * 0.97 (0.45–2.09)
22:4 1.35 (0.23–8.03) 0.57 (0.12–2.78) 1.52 (0.45–5.12)
Mono-unsaturated
fatty acids (MUFA)
18:1 n-9 (OA) 0.97 (0.83–1.14) 0.86 (0.74–0.99) * 1.04 (0.94–1.15)
Total
n-3 1.00 (0.92–1.10) 0.92 (0.85–0.99) * 1.00 (0.95–1.06)
n-6 1.01 (0.96–1.07) 1.14 (1.08–1.21) *** 1.03 (0.99–1.06)
a ATOPY: A positive SPT with a wheal read 15 min after testing that had a diameter (mean of two perpendicular
measures) of ≥3 mm more than the negative control to any allergen extract. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
Note: Each OR represents a separate regression model. Associations between serum fatty acid profiles and
asthma endpoints.
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Table 6. Multivariate logistic regression models for asthma endpoints in relation to serum phospholipid
(% weight) among fishing village inhabitants along the West Coast of South Africa.
Predictor Asthma symptoms NSBH ATOPY
n-3 series PUFAs
18:3 ALA - - 0.16 (0.00–15.72) 0.67 (0.02–25.11)
20:5 EPA 0.95 (0.79–1.14) 0.66 (0.54–0.80) *** 0.98 (0.87–1.11)
22.5 DPA 0.90 (0.45–1.80) 0.37 (0.20–0.69) ** 1.16 (0.74–1.81)
22.6 DHA 1.06 (0.91–1.24) 1.01 (0.90–1.15) 1.01 (0.92–1.12)
n-6 series PUFAs
18:2 LA 0.99 (0.93–1.06) 1.14 (1.07–1.22) *** 1.04 (0.99–1.08)
18:3 GLA 0.12 (0.00–19.42) 0.93 (0.04–24.37) 2.12 (0.19–24.08)
20:2 0.75 (0.14–4.11) 1.36 (0.47–3.98) 1.11 (0.43–2.89)
20:3 DGLA 1.14 (0.83–1.57) 1.84 (1.38–2.47) *** 1.06 (0.85–1.32)
20:4 AA 1.12 (0.98–1.27) 1.21 (1.08–1.35) *** 1.04 (0.95–1.13)
22:2 1.41 (0.46–4.32) 0.28 (0.09–0.85) * 0.96 (0.44–2.09)
22:4 1.37 (0.23–8.06) 0.48 (0.10–2.33) 1.48 (0.44–5.02)
Mono-unsaturated
fatty acids
(MUFA)
0.97 (0.83–1.14) 1 0.86 (0.74–0.99) * (0.94–1.48)
18:1 n-9 (OA)
Total
n-3 1.00(0.92–1.10) 0.92 (0.85–0.99) * 1.00 (0.95–1.06)
n-6 1.01 (0.96–1.07) 1.14 (1.08–1.21) *** 1.03 (0.99–1.60)
* Adjusted for age, gender and smoking. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Note: Each OR represents a separate
regression model that includes predictor and outcome variables adjusted for age, gender and smoking; the OR is
based on 1 unit change in measured serum fatty acid.
4. Discussion
The prevalence of asthma in this study ranged from 8–11% based on reported asthma symptoms
or a standardised definition of current asthma. This is in the same range as estimates from a
population-based survey by Ehrlich et al. (2005), which showed the prevalence of recent wheeze to
be 13.4%, asthma diagnosis 2.9% and asthma medication usage to be 6.5% among adults aged 20–44
years [37].
The prevalence of NSBH in this population was however much higher at 26%. There was a
clear sex difference with respect to the prevalence of NSBH, which was twice as common in women
compared to men (30% versus 14%) (Supplementary Table S1). The association between female
sex and NSBH has also been reported in previous studies with a threefold higher prevalence in
women compared to men in a population-based study in South Africa (OR, 3.6; 95% CI, 1.8–7.0) [38].
Gender differences in asthma epidemiology and severity is well known and is in part related to the
difference in immune responses and regulation between the two sexes [39–41]. Koper et al. have also
suggested a role for sex hormones in their study looking at gender aspects and hormonal influence
on bronchial asthma. The study concluded that female sex hormones and their receptors may favour
asthma development. Whilst a dose response relationship could not be ascertained, asthma in the
perimenstrual period was influenced by dynamic changes in oestrogen levels [42]. In this population,
occupational factors such as gender-based job allocations in the seafood-processing industry may
also result in women potentially experiencing higher exposures to respiratory irritants and allergens
and therefore being more at risk of developing asthma [43]. Of interest too is the high prevalence
of smoking among a relatively young predominantly female worker population (62%), which is
considerably higher than the population norm of 34% for the South African population at the time of
the study [37].
Studies evaluating the relationship between fish intake and serum PUFAs have shown inconsistent
results with Welch et al. suggesting that fish and fish oil consumption only accounted for about 25%
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of the variation in plasma n-3 levels [23]. In contrast other studies. demonstrated that habitual
fish intake is reflected in the content of EPA and DHA in serum and in the LDL phospholipid and
cholesteryl esters fractions. The blood concentrations of very-long-chain n-3 fatty acids are therefore
useful biomarkers for dietary fish intake [22,44]. In a population with high fish consumption and low
socioeconomic status, such as this study population, it is likely that marine oils form the main source
of n-3 PUFAs in the diet of these communities.
In this study, the n-6 PUFAs dihomo-γ-linolenic acid (DGLA), linoleic acid (LA) and arachidonic
acid (AA) were associated with an increase in the risk of NSBH. Woods et al. also demonstrated
that DGLA was associated with an increased risk for asthma, current asthma and doctor-diagnosed
asthma [24]. The lack of consistency across asthma outcomes in our study compared to that of
Woods et al. may in part be due to the different asthma definitions to the former study and the smaller
study population. However, the general trend though is consistent with a biologically plausible
pro-inflammatory role of certain n-6 PUFAs in the pathogenesis of asthma. Similarly, the inverse
association of n-3 PUFAs, with NSBH in particular, suggests that diets rich in EPA and DPA may
confer some protection against the development of asthma. This effect is biologically plausible since
n-3 PUFAs shunt eicosanoid production away from the arachidonic pathway resulting in a decreased
production of bronchoconstrictive leukotrienes [8]. However the conversion from n-3 precursors to
long chain PUFAs is not a very active pathway and it is highly recommended to take preformed EPA
(plus DHA) from fish or seafood sources.
The relatively high prevalence of atopy in this study is driven in the main by the high prevalence of
sensitization to house dust mite generally found among coastal populations. There was no relationship
between serum fatty acid levels and atopy in this population. This is similar to the findings by the
study of Woods et al. that used a comparable definition of atopy [24]. The review by Sala-Villa et al.
concludes that current data do not support the hypothesis that atopy is associated with high n-6 PUFAs
levels [45]. Similarly, consistent evidence for the association between low n-3 PUFAs and atopy is also
lacking in adults.
The current study allowed for the examination of the relationship between serum fatty acid
levels and asthma risk in a coastal working population using various tools including self-reported
symptoms, spirometry, blood analysis and non-specific inhalation challenge tests to develop outcome
variables for asthma. Whilst the standardised ECHRS definition for current asthma was used, it is
recognized that dichotomous definitions of asthma based on symptoms may be less sensitive than
using a continuous asthma score. The small sample also resulted in few cases presenting with this
outcome of interest which led to a lack of power in the study. The use of specific symptoms furthermore
also ignores the fact that asthma is a heterogenous disease with varying phenotypes [27].
The use of spirometry-based diagnoses using NSBH is a strength of this study and represents
an attempt to overcome some of the biases related to the use of self-reported symptoms in defining
asthma outcomes. Similarly, the measurement and use of serum fatty acid levels as a measure of
dietary intake could also be considered a more objective measure than food frequency questionnaires,
which are qualitatively imprecise and may perform differently in diverse study settings [46].
A recognised limitation of the study was that the categorization of the data collected on seafood and
fish consumption did not allow for accurate quantification of the consumption of seafood resulting in
difficulty with regard to their interpretation. As a result, this did not allow for the evaluation of the effect
of dietary intake on asthma risk. Due to resource constraints, data was not collected on contaminants
present in fish. It is known that contaminants such as methylmercury, lead, polychlorinated biphenyls
(PCB’s) and perfluorinated chemicals (PFC’s) may negatively influence the potentially beneficial effect
of n-3 PUFAs on asthma risk [25]. However, the seafoods most commonly eaten in this population
are likely to be very low in mercury and PCBs and therefore contaminants are unlikely to have had a
major effect. Whilst there are limited measurements of contaminants and heavy metal content in fish
species found in waters of the African coast, the befits of fish and seafood intake generally outweighs
the potential risks [47,48]. Furthermore, the lack of information on other potential confounders such as
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body mass index, recent use of fatty acid supplements, family history of asthma, antioxidant intake and
total energy intake may have constrained further analysis of the data [24,46]. This may have introduced
a degree of bias with uncertain impact on final estimates generated in this study. However, the study
population does represent a fairly homogenous group of workers of relatively low socio-economic
status in which fatty acid or antioxidant supplementation is unlikely to occur due to the cost of such
supplements. Moreover, Keever et al. in their study of Dutch adults found that supplementation did
not confound the relationship between dietary fatty acid intake and FEV1 [24,46]. A further limitation
is the cross-sectional nature of the study design, which remains susceptible to reverse causation as
temporality cannot be established due to the once-off collection of data. The small sample size may also
have rendered the study underpowered and influenced the estimates shown, with some associations
occurring due to chance alone. For this reason, the outcome for current asthma based on an ECRHS
definition was excluded from the regression analysis (available as Supplementary Material). Since this
study was performed in an occupational setting, consideration has to be given to the healthy worker
effect and how large an impact this would have had on the prevalence of asthma in this population.
Workers with asthma outcomes may have left the industry influencing the prevalence and estimates
generated in this study. There was however similarity between the estimates for asthma prevalence
obtained in the current study and that found in a national survey, and it was therefore considered
unlikely to substantially affect the risk estimates [37].
5. Conclusions
This study demonstrated, that n-3 fatty acids (EPA and DPA) are associated with decreased
NSBH risk, while certain n-6 fatty acids (LA, DGLA and AA) are associated with an increased risk
of NSBH. However, further clarity needs to be obtained on the role of specific PUFAs and how to
optimize the intake of long-chain n-3 fatty acids, especially those from fish and seafood sources,
to decrease the negative consequences of n-6 fatty acids in influencing asthma outcomes, with a specific
focus on important co-factors such as NSBH. A life course approach in such investigations may be
more useful since the associations may well differ between children and adults. Further research is
needed to evaluate the relationship between serum n-3’s and asthma risk in adults to ascertain whether
a protective effect truly exists. Such studies need to include validated questionnaires on intake of foods
rich in n-3 PUFA, adequate information on confounders such as body mass index, supplementation
nutrients and the possible role of contaminants within fish.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/16/1/43/s1,
Table S1, Adjusted logistic regression models for asthma endpoints stratified by gender and adjusted for age and
smoking. Table S2, Unadjusted logistic regression models for asthma endpoints in relation serum phospholipid
(% weight) among fishing village inhabitants along the West Coast of South Africa.
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